menu search

ONL Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for ONL1204 Ophthalmic Solution

ONL Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for ONL1204 Ophthalmic Solution
First-in-class small molecule Fas inhibitor with unique mechanism of action is designed to provide neuroprotection for retinal cells ANN ARBOR, Mich., Feb. 01, 2023 (GLOBE NEWSWIRE) — ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the U.S. Food and Drug Administration (FDA) […] The post ONL Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for... Read More
Posted: Feb 1 2023, 12:00
Author Name: forextv
Views: 102025

Search within

Pages Search Results: